Exhibit 107

Calculation of Filing Fee Tables

Form S-3

(Form Type)

Salarius Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Table 1: Newly Registered and Carry Forward Securities

						Security Type						Security Class Title						Fee Calculation or Carry Forward Rule						Amount Registered (1)						Proposed Maximum Offering Price per Share (2)						Maximum Aggregate Offering Price (1)						Fee Rate						Amount of Registration Fee						Carry Forward Form Type						Carry Forward File Number						Carry Forward Initial Effective Date						Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward
Newly Registered Securities
Fees to be Paid						Equity						Common Stock, par value $0.0001 per share						Rule 457(c)						11,163,637 (3)						$1.445						$16,131,455.50						0.00011020						$1,778.00						-						-						-						-
Fees Previously Paid						-						-						-						-						-						-						-						-						-						-						-						-
Carry Forward Securities
Carry Forward Securities						-						-						-						-												-																		-						-						-						-
						Total Offering Amounts																														$16,131,455.50												$1,778.00
						Total Fees Previously Paid																																										-
						Total Fee Offsets																																										-
						Net Fee Due																																										$1,778.00

(1)			Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also covers any additional securities that may be offered, issued or become issuable in connection with any stock split, stock dividend or similar transaction or pursuant to anti-dilution provisions of any of the securities.

(2)			Estimated solely for the purpose of calculation of the registration fee pursuant to Rule 457(c) under the Securities Act based on a per share price of $1.445, the average of the high and low reported sales prices of Salarius Pharmaceuticals, Inc.’s (the “Company”) common stock, par value $0.0001 per share (“Common Stock”), on the Nasdaq Capital Market on May 22, 2023.
(3)			Consists of (i) 330,000 shares of Common Stock issued in a private placement on May 16, 2023 (the “Private Placement”), pursuant to that certain Securities Purchase Agreement by and between the Company and an accredited investor, dated as of May 11, 2023 (the “Securities Purchase Agreement”), (ii) 3,306,364 shares of Common Stock issuable upon the exercise of the pre-funded warrants issued in the Private Placement pursuant to the Securities Purchase Agreement, (iii) 3,636,364 shares of Common Stock issuable upon the exercise of the Series A-1 warrants issued in the Private Placement pursuant to the Securities Purchase Agreement, (iv) 3,636,364 shares of Common Stock issuable upon the exercise of the Series A-2 warrants issued in the Private Placement pursuant to the Securities Purchase Agreement, and (v) 254,545 shares of Common Stock issuable upon the exercise of the placement agent warrants issued to the Company’s placement agent in connection with the Private Placement.